Efficacy and Safety of Duloxetine, Placebo and Pelvic Floor Muscle Training in Subjects With Stress Urinary Incontinence

Incontinence Quality of Life scores from baseline to endpoint.

Patient Global Impression - Impression at endpoint.

Symptoms Frequency & Bothersomeness.

Percent change in weekly continence pad usage (CPAD) from baseline to endpoint.

Change in Patient Satisfaction Questionnaires -2 and -4 questionnaire scores from baseline to endpoint.

Percent change in daily CPAD from baseline to endpoint.

Compare safety of duloxetine with placebo based on vital signs , laboratory values and the occurrence of treatment-emergent adverse events.

Compare combined duloxetine and PFMT, combined duloxetine and imitation PFMT, combined placebo with PFMT and combined placebo and imitation PFMTwith respect to efficacy and to safety.

Compare the effect of duloxetine and placebo on patient compliance to PFMT and imitation PFMT regimes using a daly patient-generated log of completed contractions.

Generate long-term safety data (during open-label extension) on duloxetine in the treatment of women with SUI.